Mankind Pharma Share Price In Focus Following Launch Of Rs 3,000 Crore QIP For BSV Acquisition; BUY?

Mankind Pharma, India's fourth-largest pharmaceutical company by domestic sales, has officially launched its Rs 3,000 crore Qualified Institutional Placement (QIP) to partly fund the acquisition of Bharat Serums and Vaccines (BSV), a deal valued at Rs 13,630 crore.

QIP Details and Pricing

On Monday, December 16, Mankind Pharma's board approved the opening of the QIP with a floor price set at Rs 2,616.55 per share, determined as per SEBI's pricing formula under the (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company has the flexibility to offer a discount of up to 5% on the floor price for qualified institutional buyers (QIBs).

The final issue price will be determined in consultation with the appointed book-running lead managers, Kotak Mahindra Capital and IIFL Capital, who are advising on the issue. Mankind Pharma also adopted its preliminary placement document and application form on December 16, aligning with applicable regulatory guidelines, including the Companies Act, 2013.

The QIP, which opened on December 16, is expected to attract interest from institutional investors given the company's robust growth trajectory, strategic acquisition plans, and solid market performance.

Fund Utilization

Mankind Pharma has earmarked the funds raised from the QIP to part-finance its acquisition of Bharat Serums and Vaccines (BSV), a pharmaceutical company specializing in women's health, critical care, and assisted reproductive technology. The acquisition was announced earlier in July.

In addition to funding the acquisition, the company will use part of the QIP proceeds for repayment or pre-payment of certain outstanding borrowings and for general corporate purposes.

Stock Performance

Ahead of the QIP announcement, Mankind Pharma's shares gained 1.7% on Monday, closing at Rs 2,686 on the NSE. The stock has delivered a healthy performance, surging nearly 40% in the past year and boosting the company's market capitalization to Rs 1.08 lakh crore.

However, post-announcement, the stock traded with marginal cuts of 1% at Rs 2,690.55 per share as of 11:30 am on Tuesday, December 17, indicating a cautious yet optimistic sentiment among investors. Despite the slight dip, the stock has delivered 36% returns in 2024 alone.

Financial Trajectory

Mankind Pharma has demonstrated robust financial performance in recent quarters. In Q2 FY25, the company reported a 30.43% surge in consolidated net profit to Rs 653.47 crore, driven by a 13.6% rise in revenue to Rs 3,076.51 crore, compared to the same period last year.

Market Presence

Mankind Pharma operates at the intersection of pharmaceutical formulations and consumer healthcare, delivering quality products at affordable prices. The company's 25 manufacturing facilities across India produce a diverse range of dosage forms, including tablets, capsules, syrups, vials, ampoules, soft gels, eye drops, creams, contraceptives, and over-the-counter (OTC) products.